Tag Archives: Supreme Pharmaceuticals

BlissCo Cannabis

Supreme Pharmaceuticals Inc. Changes Name to The Supreme Cannabis Company, Inc. and Announces Conversion of Approximately $17.4 Million Aggregate Principal Amount of 10% Unsecured Convertible Debentures Due 2019

Supreme Pharmaceuticals Inc. Changes Name to The Supreme Cannabis Company, Inc. and Announces Conversion of Approximately $17.4 Million Aggregate Principal Amount of 10% Unsecured Convertible Debentures Due 2019

TORONTO, Ontario, Dec. 18, 2017 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (TSXV: FIRE) is pleased to announce that is has changed its name to “The Supreme Cannabis Company, Inc.” effective today. The name change was approved by the shareholders of the Company at the annual general and special meeting of shareholders held earlier today.

BlissCo Cannabis

Supreme Purchases Adjacent Land for Ultra-Premium Cannabis Facility

TORONTO, Ontario, Dec. 18, 2017 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme or the “Company”) (TSXV:FIRE) is pleased to announce the purchase of an approximately six acre property adjacent to the 7ACRES facility in Kincardine, Ontario.

BlissCo Cannabis

Supreme Commences Production in New Flowering Rooms

TORONTO, Ontario, Nov. 7, 2017 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (TSXV: FIRE) is pleased to announce 7ACRES has commenced production in the newly constructed flowering rooms recently approved by Health Canada.

BlissCo Cannabis

Supreme Pharmaceuticals Announces $30 Million Bought Deal Private Placement of Convertible Debenture Units

TORONTO, Ontario, Oct. 17, 2017 /Weed Wire/ – Supreme Pharmaceuticals Inc. (the “Company”) (TSXV:FIRE) announced today that it has entered into an agreement with Canaccord Genuity Corp., as lead underwriter on behalf of a syndicate of underwriters (the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought deal, private placement basis, $30,000,000 aggregate principal amount of convertible debenture units (the “Convertible Debenture Units”) at a price of $1,000 per Convertible Debenture Unit.

bayfield strategy 7ACRES Hybrid Facility

Supreme to Quadruple Capacity at 7ACRES Hybrid Facility

TORONTO, Ontario, Oct. 4, 2017 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (TSXV: FIRE) is pleased to announce that 7ACRES has completed construction of three additional 10,000 sq. ft. flowering rooms at its Hybrid Facility, and applied to Health Canada for licensing.

bayfield strategy 7ACRES Hybrid Facility

Supreme Engages Leading Financial Communications Firm Bayfield Strategy

TORONTO, Ontario, Sept. 28, 2017 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (TSXV: FIRE) is pleased to announce that it has retained Bayfield Strategy, Inc. (“Bayfield”) to provide comprehensive Investor and Public Relations.

SP Fire Emerald Health Leadership Team

Supreme Strengthens Leadership Team to Prepare for Next Stage of Growth

TORONTO, Ontario, Sept. 26, 2017 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (TSXV: FIRE) is pleased to announce exciting changes and additions to our senior leadership team as the Company prepares for growth.

Emerald Health Northern Vine Labs

Emerald Health Therapeutics Expands its Cannabis Supply with Purchase from Supreme Pharmaceuticals

VICTORIA, British Columbia, Sept. 20, 2017 /Weed Wire/ — Emerald Health Therapeutics Inc. (EHT) (TSXV: EMH; OCTQX: EMHTF) today announced that its wholly owned subsidiary, Emerald Health Botanicals Inc., has completed a purchase of dried cannabis from Supreme Pharmaceuticals Inc.’s (Supreme) (TSXV: FIRE) subsidiary, 7ACRES.

SP Fire Emerald Health Leadership Team

Supreme Completes Sale with Emerald Health Botanicals Inc.

TORONTO, Ontario, Sept. 20, 2017 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (TSXV:FIRE) is pleased to announce its wholly owned subsidiary, 7ACRES, has completed a sale of dried cannabis to Emerald Health Botanicals Inc.

Green bubble? Cannabis investors on white-knuckle ride as share prices fall

Green Bubble? Cannabis Investors on White-Knuckle Ride as Share Prices Fall

Canadian marijuana stocks have been on a punishing slide for three straight months despite a temporary blip of investor fever in April that sent share prices soaring to record highs as Ottawa tabled legislation to legalize pot.

SP Fire Emerald Health Leadership Team

Supreme Announces Listing of Common Shares on the TSX.V under the symbol “FIRE”

TORONTO, Ontario, June 1, 2017 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (CSE:SL)(CSE:SL.CN)(CNSX:SL)(OTC PINK:SPRWF) is pleased to announce that it has received final approval from the TSX Venture Exchange (“TSX.V”) to list the Company’s common shares on the TSX.V. The common shares are expected to begin trading on the TSX.V at the opening of markets on June 6, 2017 under the symbol “FIRE”.

Supreme Updates Board of Directors

Supreme Announces Conditional Approval to List on the TSX.V

TORONTO, Ontario, April 10, 2017 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (CSE:SL)(CSE:SL.CN) is pleased to announce that it has received conditional approval from the TSX Venture Exchange (“TSX.V”) to list the Company’s common shares on the TSX.V.

Supreme Pharma

Supreme Pharmaceuticals Closes $55 Million Offering

TORONTO, Ontario, Dec. 13, 2016 /Weed Wire/ — Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (CSE:SL) is pleased to announce the closing of its $50 million bought deal private placement (the “Brokered Offering”) and concurrent $5 million non-brokered private placement (together with the Brokered Offering, the “Offering”) for aggregate gross proceeds of $55 million.

Supreme Pharma

Supreme Closes Private Placement for Aggregate Proceeds of $14,949,755

TORONTO, Ontario, Aug. 30, 2016 /Weed Wire/ — Supreme Pharmaceuticals Inc. (the “Company” or “Supreme”) (CSE:SL)(OTC PINK:SPRWF) is pleased to announce it has closed the third tranche of its previously announced non-brokered private placement (the “Financing”) for proceeds of $10,610,625 and aggregate proceeds from three tranches of $14,949,755.

Supreme Pharma

Supreme Obtains MMPR License to Cultivate Medical Marijuana

TORONTO, ON, March 11, 2016 /Weed Wire/ — Supreme Pharmaceuticals Inc. (the “Company” or “Supreme”) (OTC PINK:SPRWF)(CSE:SL) is pleased to announce its wholly-owned subsidiary, Advanced Medical Marihuana Canada (“AMMCan”) has been granted a license to cultivate medical marijuana pursuant to the Marihuana for Medical Purposes Regulations (the “MMPR”).


Top